On June 12, WUXI BIO (02269) spent 99.7766 million Hong Kong dollars to repurchase 3.269 million shares.
WuXi Biologics (02269) announced that it would spend 99.7766 million Hong Kong dollars to repurchase 3.269 million shares on June 12, 2026.
Wuxi Bio (02269) announced on June 12, 2026 that it will repurchase 3.269 million shares at a cost of 99.77 million Hong Kong dollars.
On June 12, 2026, the company issued 21,000 shares in accordance with the pre-emptive rights plan adopted by the company on January 5, 2016 (revised on August 10, 2016).
Related Articles
Buying low on Shenzhen Hepalink Pharmaceutical Group (09989) for two consecutive months, will the Hong Kong Stock Connect funds soon witness the reversal of the heparin cycle?
New Stock News | Leading supply chain company Andes Zhilian's Hong Kong IPO prospectus updated, achieving double high increase in revenue and net profit.
How strong is the demand for SpaceX (SPCX.US) IPO? Oversubscribed subscriptions, "greenshoe" exemption from commission, and options expected to open next week!
Buying low on Shenzhen Hepalink Pharmaceutical Group (09989) for two consecutive months, will the Hong Kong Stock Connect funds soon witness the reversal of the heparin cycle?
New Stock News | Leading supply chain company Andes Zhilian's Hong Kong IPO prospectus updated, achieving double high increase in revenue and net profit.
How strong is the demand for SpaceX (SPCX.US) IPO? Oversubscribed subscriptions, "greenshoe" exemption from commission, and options expected to open next week!
RECOMMEND
